

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 17, 2016**

---

**Bellicum Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36783**  
(Commission  
File Number)

**20-1450200**  
(IRS Employer  
Identification No.)

**2130 W. Holcombe Blvd., Ste. 800**  
**Houston, TX**  
(Address of principal executive offices)

**77030**  
(Zip Code)

**Registrant's telephone number, including area code: (832) 384-1100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On May 17, 2016, upon recommendation of the Nominating and Governance Committee of the Board of Directors (the “Board”) of Bellicum Pharmaceuticals, Inc. (the “Company”), the Board appointed James M. Daly as a Class III director to serve in such capacity until the Company’s 2017 annual meeting of stockholders.

Mr. Daly will receive compensation for his service as a director in accordance with the Company’s Non-Employee Director Compensation Policy (the “Compensation Policy”). The Compensation Policy provides for annual cash compensation of \$35,000 for service on the Board, payable in equal quarterly installments and pro rated based on days served in the applicable fiscal year. Upon his appointment to the Board, Mr. Daly received a stock option to purchase 20,000 shares of the Company’s common stock in accordance with the Compensation Policy, which will vest in equal monthly installments over a three year period. Pursuant to the Compensation Policy, Mr. Daly also received a stock option to purchase 833 shares of the Company’s common stock, which will vest upon the date of the Company’s 2016 annual meeting of stockholders. The Compensation Policy also provides for further automatic stock option grants to purchase 10,000 shares of the Company’s common stock on the date of each annual meeting of stockholders, which will vest in equal monthly installments until the subsequent annual meeting of stockholders. Mr. Daly has also entered into our standard form of indemnification agreement.

Mr. Daly, age 55, currently serves on the board of directors of three biopharmaceutical companies, including ACADIA Pharmaceuticals, Inc., Halozyme Therapeutics, Inc. and Chimerix, Inc. From October 2012 to June 2015, Mr. Daly served as Executive Vice President and Chief Commercial Officer of Incyte Corporation, a public biotechnology company. From January 2002 to December 2011, Mr. Daly held various positions at Amgen, Inc., a public biopharmaceutical company, where he most recently served as Senior Vice President of North America Commercial Operations and Global Marketing/Commercial Development. Prior to his employment with Amgen, Mr. Daly served as Senior Vice President and General Manager of the Respiratory/Anti-infective business unit of GlaxoSmithKline, a public pharmaceutical company, where he was employed from June 1985 to December 2001. Mr. Daly received his B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.

A copy of the press release announcing Mr. Daly’s appointment to the Board is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated May 18, 2016.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Bellicum Pharmaceuticals, Inc.**

Dated: May 18, 2016

By: /s/ Ken Moseley

Ken Moseley,

Senior Vice President and General Counsel

## INDEX TO EXHIBITS

**Exhibit No.**

---

**Description**

---

99.1

Press Release dated May 18, 2016.

## **Bellicum Appoints Jim Daly to its Board of Directors**

**HOUSTON, TX—May 18, 2016**—Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.

“We are pleased to welcome an executive with Jim’s extensive senior leadership experience to our Board of Directors,” said Tom Farrell, President and Chief Executive Officer of Bellicum. “His expertise in global marketing and commercial development, including the launch of many important therapeutics, particularly in oncology, will be invaluable as we continue to advance our pipeline of T cell immunotherapies.”

Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015, where he was instrumental in commercializing and driving product growth of Jakafi®— the first drug approved by the U.S. FDA for patients with a certain chronic type of bone marrow disease. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier at Amgen, he also served as Vice President and General Manager of the Oncology Business Unit, and led his team to the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®.

Earlier in his career, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®.

Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.

## **About Bellicum Pharmaceuticals**

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at [www.bellicum.com](http://www.bellicum.com).

## **Forward-Looking Statement**

*This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, or current expectations concerning, among other things, our research and development activities relating to the advancement and potential commercialization of our products under development. Various factors may cause differences between Bellicum's expectations and actual results as discussed in greater detail under the heading "Risk Factors" in Bellicum's filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2015. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.*

## **Investors:**

Bellicum Pharmaceuticals, Inc.  
Alan Musso, CFO  
832-384-1116  
[amusso@bellicum.com](mailto:amusso@bellicum.com)

## **Media:**

BMC Communications  
Brad Miles, 646-513-3125  
[bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)